Eli Lilly (LLY)

948.45
-26.51 (-2.72%)
NYSE · Last Trade: May 9th, 2:07 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close974.96
Open974.07
Bid949.80
Ask950.60
Day's Range947.51 - 980.00
52 Week Range623.78 - 1,133.95
Volume3,559,176
Market Cap907.27B
PE Ratio (TTM)41.33
EPS (TTM)22.9
Dividend & Yield6.920 (0.73%)
1 Month Average Volume3,285,592

Chart

About Eli Lilly (LLY)

Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More

News & Press Releases

GoodRx (GDRX) Q1 2026 Earnings Call Transcriptfool.com
GoodRx (GDRX) Q1 2026 Earnings Call Transcript
Via The Motley Fool · May 8, 2026
Omada Health (OMDA) Q1 2026 Earnings Transcriptfool.com
Omada Health (OMDA) Q1 2026 Earnings Transcript
Via The Motley Fool · May 8, 2026
Will Eli Lilly Be the First $2 Trillion Healthcare Stock? 3 Catalysts That Could Get It There.fool.com
The competition is far behind.
Via The Motley Fool · May 8, 2026
Omada Health Q1 Earnings Call Highlightsmarketbeat.com
Omada Health (NASDAQ:OMDA) reported what executives described as a “milestone quarter” for the first quarter of 2026, highlighting 42% year-over-year revenue growth, expanding margins, and positive adjusted EBITDA alongside a raised full-year outlook. On the earnings call, Co-Founder and CEO Sean D
Via MarketBeat · May 8, 2026
Eli Lilly's Retatrutide Is So Hot, The Unlaunched Weight-Loss Drug Is Already Getting Knocked Offinvestors.com
Eli Lilly's next obesity drug, retatrutide, is so popular it's already getting copied. Can Lilly compete with its own drug?
Via Investor's Business Daily · May 8, 2026
How This Eli Lilly-Tied IPO Stock Fared In Its First Quarterinvestors.com
IPO stock Omada Health easily beat first-quarter sales expectations Thursday, and announced a deal with drug titan Eli Lilly.
Via Investor's Business Daily · May 7, 2026
Forget Eli Lilly: These 2 Stocks Have More Upsidefool.com
Eli Lilly has a lofty valuation thanks to its strong GLP-1 growth, but don't count out these two competitors.
Via The Motley Fool · May 7, 2026
Eli Lilly Now Has the World's Best-Selling Drug -- But Does That Make the Stock a No-Brainer Buy?fool.com
Mounjaro generated $8.66 billion in sales in the first quarter.
Via The Motley Fool · May 7, 2026
What the FDA's Latest Proposal Means for Lilly, Novo, and Himsmarketbeat.com
The FDA's latest proposal would be a win for Eli Lilly and Novo Nordisk, while Hims & Hers Health would also garner indirect benefits.
Via MarketBeat · May 7, 2026
My Top Obesity Stock to Buy and Holdfool.com
Most weight-loss stocks are built on future expectations. Eli Lilly is built on current earnings and expanding demand.
Via The Motley Fool · May 7, 2026
Eli Lilly To Invest $4.5 Billion More In Indiana Manufacturing Sitesbenzinga.com
Eli Lilly plans to invest $4.5 billion in Indiana, expanding its U.S. manufacturing footprint and supporting new weight-loss treatments.
Via Benzinga · May 7, 2026
ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A...
Via StockStory · May 6, 2026
Do Wall Street Analysts Like Eli Lilly Stock?
While Eli Lilly has slightly lagged behind the SPX over the past year, Wall Street analysts maintain a bullish outlook on the stock’s prospects.
Via Barchart.com · May 6, 2026
Elanco’s (NYSE:ELAN) Q1 CY2026 Sales Beat Estimates
Animal health company Elanco (NYSE:ELAN) announced better-than-expected revenue in Q1 CY2026, with sales up 14.9% year on year to $1.37 billion. The company ...
Via StockStory · May 6, 2026
Collegium Pharmaceutical (COLL) Q1 Earnings Report Preview: What To Look For
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before market open. Here’s what investors sho...
Via StockStory · May 5, 2026
Zoetis (ZTS) Q1 Earnings: What To Expect
Animal health company Zoetis (NYSE:ZTS) will be announcing earnings results this Thursday morning. Here’s what you need to know. Zoetis beat analysts’ revenu...
Via StockStory · May 5, 2026
Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be announcing earnings results this Thursday after market hours. Here’s what investors sho...
Via StockStory · May 5, 2026
Earnings To Watch: Viatris (VTRS) Reports Q1 Results Tomorrow
Medication company Viatris (NASDAQ:VTRS) will be announcing earnings results this Thursday before the bell. Here’s what investors should know. Viatris beat a...
Via StockStory · May 5, 2026
Schrödinger (SDGR) Q1 2026 Earnings Transcriptfool.com
Schrödinger (SDGR) Q1 2026 Earnings Transcript
Via The Motley Fool · May 5, 2026
Eli Lilly Advances As Inflammatory Bowel Disease Drug Reinforces Long-Term Confidencebenzinga.com
Eli Lilly shares rise as Omvoh shows 4-year disease clearance in ulcerative colitis, with consistent safety and strong Crohn's data.
Via Benzinga · May 5, 2026
3 Quality Compounders to Own for Decades
Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that genera...
Via StockStory · May 5, 2026
Elanco (ELAN) Q1 Earnings: What To Expect
Animal health company Elanco (NYSE:ELAN) will be reporting results this Wednesday before the bell. Here’s what investors should know. Elanco beat analysts’ r...
Via StockStory · May 4, 2026
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R...
Via StockStory · May 4, 2026
3 Reasons It's Not Too Late to Buy Eli Lilly Stockfool.com
The company still has a strong lead in its core therapeutic area.
Via The Motley Fool · May 4, 2026
Is Eli Lilly Stock Heading for $1,000?fool.com
Eli Lilly's valuation looks far more attractive now than it did even a year ago.
Via The Motley Fool · May 4, 2026